This is the Kator Daily Podcast for Friday, July 2nd, 2021.

I'm Caleb Brown.

It's not a blockbuster of a case, but the Supreme Court's ruling

in a patent case last month

may have big implications for federal regulating

going forward.

Cato's Tommy Barry details the case

and why it may end up delivering

more accountability to federal agencies.

We're about to get way into the weeds here.

And this is a Supreme Court decision,

United States versus Arthrex, just rolls off the tongue, but in general what was the issue that the Supreme Court is trying to address here and what's give us a little bit of the background too.

Sure, so the hard to pronounce Arthrex is a company

dealing with medical technology and stuff

I have no clue how it works.

But luckily that doesn't matter to the actual merits of the case.

The case was about the patent system and

specifically the system for canceling a patent. Someone accused Arthrex of having a

patent they shouldn't have and that went through a process set up by a statute passed about 10 years ago

where a panel of three administrative patent judges decide whether to essentially

cancel a patent. And the problem is that those administrative patent judges are not

nominated by the president and confirmed by the Senate. They're instead selected and

...